NeuroDawn Pharmaceutical
Developing novel drugs for central nervous system diseases
About NeuroDawn Pharmaceutical
NeuroDawn Pharmaceutical is a privately held biotechnology company founded in 2020 and based in Nanjing, China. The company focuses on the research and development of new drugs, particularly multi-acting new chemical entities and novel combinations, for treating central nervous system (CNS) diseases. It operates with an integrated internal R&D platform that encompasses chemical synthesis, biological screening, chemistry, manufacturing, and control (CMC) development, drug metabolism and pharmacokinetics (DMPK) research, and clinical research.
The company's pipeline includes treatments for conditions like acute ischemic stroke. One of its key products is the Y-3 injection, a Class 1 innovative drug designed to alleviate neurological symptoms and improve daily activities for patients with acute ischemic stroke. In August 2023, NeuroDawn entered into a collaboration agreement with China Medical System Holdings Limited, granting them exclusive promotion rights for the Y-3 injection in Mainland China, Hong Kong, and Macao.
NeuroDawn Pharmaceutical has secured significant funding, raising $53.7 million from investors including Jiangning Kechuang Group, Chunxin Capital, Fujian Huaxing Venture Capital, Red Horse Investment Group, and Tencent Investment. The company employs around 100 people and serves hospitals by providing effective treatment options for patients with neurological diseases.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 14.0/100
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BEquity / VC | Nov 2023 | $0 | — | Tencent | ↗ |
| SERIES AEquity / VC | Feb 2023 | $14M | $55M | Simcere Pharma · China Merchants Health | ↗ |
Growth signals
Latest recorded traffic for NeuroDawn Pharmaceutical is 840 monthly website visits, up 8300% over the last three months.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
NeuroDawn Pharmaceutical in the Nanjing City ecosystem
The NeuroDawn Pharmaceutical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Dynamic Balance Capital- NFNanjing Industrial Development Fund
- SBShanghai Haoyuan Biotech
Simcere Pharma
China Merchants Health
Tencent
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about NeuroDawn Pharmaceutical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NeuroDawn Pharmaceutical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.